tradingkey.logo
tradingkey.logo
Suchen

Neogenomics Inc

NEO
Zur Watchlist hinzufügen
14.970USD
+0.380+2.60%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
1.95BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Neogenomics Inc Unternehmen

NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.

Neogenomics Inc Informationen

BörsenkürzelNEO
Name des UnternehmensNeogenomics Inc
IPO-datumDec 10, 2012
CEOZook (Antony P)
Anzahl der mitarbeiter2200
WertpapierartOrdinary Share
GeschäftsjahresendeDec 10
Addresse9490 Neogenomics Way
StadtFORT MYERS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl33912
Telefon12397680600
Websitehttps://neogenomics.com/
BörsenkürzelNEO
IPO-datumDec 10, 2012
CEOZook (Antony P)

Führungskräfte von Neogenomics Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Lead Independent Director
Lead Independent Director
--
--
Mr. David B. Perez
Mr. David B. Perez
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
220.01K
+0.96%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
164.03K
+3.45%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
75.42K
+30.60%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
51.18K
+45.09%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
30.24K
+76.32%
Ms. Marjorie C. Green
Ms. Marjorie C. Green
Independent Director
Independent Director
22.96K
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Neogenomics Inc?

Die fünf größten Anteilseigner von Neogenomics Inc sind: Mr. Jeffrey Scott (Jeff) Sherman

Wie viele Institutionen halten Anteile an Neogenomics Inc (NEO)?

Mit Stand vom 2026Q1 halten 564 Institutionen Anteile an Neogenomics Inc, mit einem Gesamtmarktwert von etwa 156.61M, was 120.32% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 7515333.00 gestiegen.

Was ist die größte Einnahmequelle von Neogenomics Inc?

Am 2026Q1 erzielte das Geschäft mit Clinical Services-Client direct billing für Neogenomics Inc den höchsten Umsatz in Höhe von 518.84M, was 71.34% des Gesamtumsatzes entspricht.